MO129COMPARATIVE EFFECTIVENESS OF SGLT2I VERSUS DPP4I ON CARDIOVASCULAR AND RENAL OUTCOMES IN ROUTINE-CARE SETTINGS
Sign Up to like & getrecommendations! Published in 2021 at "Nephrology Dialysis Transplantation"
DOI: 10.1093/ndt/gfab092.007
Abstract: While clinical trials have demonstrated the efficacy of SGLT2 inhibitors on preventing cardiovascular and renal damage, few studies have expanded this evidence to routine-care settings. We compared clinical outcomes of adults who started SGLT2i or… read more here.
Keywords: sglt2i; routine care; dpp4i; cardiovascular renal ... See more keywords
Comparison of effectiveness and drug cost between dipeptidyl peptidase‐4 inhibitor and biguanide as the first‐line anti‐hyperglycaemic medication among Japanese working generation with type 2 diabetes
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Evaluation in Clinical Practice"
DOI: 10.1111/jep.13171
Abstract: Abstract Aims and Objectives Dipeptidyl peptidase‐4 inhibitor (DPP4i) is widely used for the treatment of type 2 diabetes (T2DM) in several countries such as Japan, whereas biguanide (BG; mostly metformin) is recommended as a first‐line… read more here.
Keywords: first line; dpp4i; medication; dipeptidyl peptidase ... See more keywords
Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan
Sign Up to like & getrecommendations! Published in 2017 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-017-0640-5
Abstract: BackgroundWhether dipeptidyl peptidase-4 inhibitor (DPP4i) is associated with a lower risk of new-onset atrial fibrillation (AF) in patients with diabetes remains unclear. This study aimed to evaluate the risk of AF associated with use of… read more here.
Keywords: associated lower; dpp4i users; lower risk; study ... See more keywords
In patients with type 2 diabetes the presence of Hashimoto's thyroiditis reduces the beneficial effect of dipeptidyl peptidase-4 inhibitor on plasma glucose control.
Sign Up to like & getrecommendations! Published in 2021 at "Endocrine journal"
DOI: 10.1507/endocrj.ej20-0620
Abstract: In this study, we compared the efficacy of a dipeptidyl peptidase-4 inhibitor (DPP4i) to improve glucose control in patients with type 2 diabetes mellitus (T2DM) with or without Hashimoto's thyroiditis (HT). First, we compared the… read more here.
Keywords: peptidase inhibitor; patients type; dpp4i; dipeptidyl peptidase ... See more keywords
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors vs. Dipeptidyl Peptidase-4 (DPP4) Inhibitors for New-Onset Dementia: A Propensity Score-Matched Population-Based Study With Competing Risk Analysis
Sign Up to like & getrecommendations! Published in 2021 at "Frontiers in Cardiovascular Medicine"
DOI: 10.3389/fcvm.2021.747620
Abstract: Introduction: The effects of sodium-glucose cotransporter 2 inhibitors (SGLT2I) and dipeptidyl peptidase-4 inhibitors (DPP4I) on new-onset cognitive dysfunction in type 2 diabetes mellitus remain unknown. This study aimed to evaluate the effects of the two… read more here.
Keywords: sodium glucose; dementia; study; dpp4i ... See more keywords
Primary Occurrence of Cardiovascular Events After Adding Sodium–Glucose Cotransporter-2 Inhibitors or Glucagon-like Peptide-1 Receptor Agonists Compared With Dipeptidyl Peptidase-4 Inhibitors: A Cohort Study in Veterans With Diabetes
Sign Up to like & getrecommendations! Published in 2023 at "Annals of Internal Medicine"
DOI: 10.7326/m22-2751
Abstract: BACKGROUND The effectiveness of glucagon-like peptide-1 receptor agonists (GLP1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) in preventing major adverse cardiac events (MACE) is uncertain for those without preexisting cardiovascular disease. OBJECTIVE To test the hypothesis that… read more here.
Keywords: receptor agonists; dpp4i; peptide receptor; glucagon like ... See more keywords